Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

AZNAstraZenecaRunning, no new patients

D9319C00001- 1L OC Mono Global RCT

Ovarian Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 3
Patients
366 (final count)
Started
May 31, 2021
Main results expected
Jul 27, 2026
Fully finished
Jul 27, 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment.

    Measured over: Approximately 3 years

  • Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard 1st line platinum-based chemotherapy treatment.

    Measured over: Approximately 3 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT04884360 · record last updated 2026-03-02 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04884360) ↗